Identification and characterization of human UDP-glucuronosyltransferases responsible for the glucuronidation of fraxetin

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2014, Pages 135-140

  Xia, Yang Liu ^a,b   Liang, Si Cheng ^a,b   Zhu, Liang Liang ^a   Ge, Guang Bo ^a   He, Gui Yuan ^a   Ning, Jing ^a   Lv, Xia ^a   Ma, Xiao Chi ^c   Yang, Ling ^a   Yang, Sheng Li ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Fraxetin; Glucuronidation; Human liver microsomes (HLMs); UDP glucuronosyltransferases (UGTs); UGT1A9

Indexed keywords

7 O GLUCURONIDE; 7,8 DIHYDROXYLCOUMARIN; 8 O GLUCURONIDE; COUMARIN DERIVATIVE; DRUG METABOLITE; FRAXETIN; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; PLANT MEDICINAL PRODUCT; UNCLASSIFIED DRUG; ISOENZYME; RECOMBINANT PROTEIN; UDP-GLUCURONOSYLTRANSFERASE 1A9;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CATALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG GLUCURONIDATION; ENZYME ASSAY; ENZYME INHIBITION; ENZYME KINETICS; HUMAN; HUMAN TISSUE; LIVER MICROSOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTON NUCLEAR MAGNETIC RESONANCE; BIOTRANSFORMATION; ENZYME SPECIFICITY; ENZYMOLOGY; KINETICS; LIVER; METABOLIC CLEARANCE RATE; METABOLISM;

BIOTRANSFORMATION; COUMARINS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KINETICS; LIVER; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY;

EID: 84901198170     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-059     Document Type: Article

References (23)

1. Wua, C. R., Huang, M. Y., Lin, Y. T., Ju, H. Y. and Ching, H.: Antioxidant properties of Cortex Fraxini and its simple coumarins. Food Chem., 104: 1464-1471 (2007).
2. Martin-Aragon, S., Benedi, J. and Villar, A.: Modifications on antioxidant capacity and lipid peroxidation in mice under fraxetin treatment. J. Pharm. Pharmacol., 49: 49-52 (1997).
3. Molina-Jiménez, M. F., Sánchez-Reus, M. I., Andres, D., Cascales, M. and Benedi, J.: Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. Brain Res., 1009: 9-16 (2004).
4. Thuong, P. T., Pokharel, Y. R., Lee, M. Y., Kim, S. K., Bae, K., Su, N. D., Oh, W. K. and Kang, K. W.: Dual anti-oxidative effects of fraxetin isolated from Fraxinus rhinchophylla. Biol. Pharm. Bull., 32: 1527-1532 (2009).
5. Nykolov, N., Iossifova, T., Vassileva, E., Kostova, I. and Stoev, G.: Reverse-phase high pressure liquid chromatographic analysis of hydroxycoumarins in plant extracts. Quantitative determination of hydroxycoumarins in fraxinus ornus. Phytochem. Anal., 4: 86-88 (1993).
6. Yasuda, T., Fukui, M., Nakazawa, T., Hoshikawa, A. and Ohsawa, K.: Metabolic fate of Fraxin administered orally to rats. J. Nat. Prod., 69: 755-757 (2006).
7. Liang, S. C., Ge, G. B., Liu, H. X., Zhang, Y. Y., Wang, L. M., Zhang, J. W., Yin, L., Li, W., Fang, Z. Z., et al.: Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of daphnetin. Drug Metab. Dispos., 38: 973-980 (2010).
8. Tukey, R. H. and Strassburg, C. P.: Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 40: 581-616 (2000).
9. Loureiro, A. I., Bonifacio, M. J., Fernandes-Lopes, C., Almeida, L., Wright, L. C. and Soares-Da-Silva, P.: Human metabolism of nebicapone (BIA3-202), a novel catechol-O-methyltransferase inhibitor: Characterization of in vitro glucuronidation. Drug Metab. Dispos., 34: 1856-1862 (2006).
10. Miners, J. O., Bowalgaha, K., Elliot, D. J., Baranczewski, P. and Knights, K. M.: Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDP-glucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab. Dispos., 39: 644-652 (2011).
11. Zhu, L. L., Ge, G. B., Liu, Y., He, G. Y., Liang, S. C., Fang, Z. Z., Dong, P. P., Cao, Y. F. and Yang, L.: Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica, 42: 1001-1008 (2012).
12. Uchaipichat, V., Winner, L. K., Mackenzie, P. I., Elliot, D. J., Williams, J. A. and Miners, J. O.: Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br. J. Clin. Pharmacol., 61: 427-439 (2006).
13. Natsume, M., Osakabe, N., Oyama, M., Sasaki, M., Baba, S., Nakamura, Y., Osawa, T. and Terao, J.: Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free Radic. Biol. Med., 34: 840-849 (2003).
14. Lv, X., Wang, C. Y., Hou, J., Zhang, B. J., Deng, S., Tian, Y., Huang, S. S., Zhang, H. L., Shu, X. H., et al.: Isolation and identification of metabolites of osthole in rats. Xenobiotica, 42: 1120-1127 (2012).
15. Uchaipichat, V., Mackenzie, P. I., Guo, X. H., Gardner-Stephen, D., Galetin, A., Houston, J. B. and Miners, J. O.: Human UDP- glucuronosyltransferases: Isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos., 32: 413-423 (2004).
16. Bock, K. W., Gschaidmeier, H., Heel, H., Lehmkoster, T., Munzel, P. A. and Bock-Hennig, B. S.: Functions and transcriptional regulation of PAH-inducible human UDP-glucuronosyltransferases. Drug Metab. Rev., 31: 411-422 (1999).
17. Ebner, T. and Burchell, B.: Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos., 21: 50-55 (1993).
18. Radominska-Pandya, A., Czernik, P., Little, J. M., Battaglia, E. and Mackenzie, P. I.: Structural and functional studies of UDP- glucuronosyltransferases. Drug Metab. Rev., 31: 817-900 (1999).
19. Bowalgaha, K. and Miners, J. O.: The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br. J. Clin. Pharmacol., 52: 605-609 (2001).
20. Harbourt, D. E., Fallon, J. K., Ito, S., Baba, T., Ritter, J. K., Glish, G. L. and Smith, P. C.: Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry. Anal. Chem., 84: 98-105 (2012).
21. Guo, X. J., Zhang, X. L., Feng, J. T., Guo, Z. M., Xiao, Y. S. and Liang, X. M.: Purification of saponins from leaves of Panax notoginseng using preparative two-dimensional reversed-phase liquid chromatography/hydrophilic interaction chromatography. Anal. Bioanal. Chem., 405: 3413-3421 (2013).
22. Shiratani, H., Katoh, M., Nakajima, M. and Yokoi, T.: Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab. Dispos., 36: 1745-1752 (2008).
23. Liang, S. C., Ge, G. B., Liu, H. X., Shang, H. T., Wei, H., Fang, Z. Z., Zhu, L. L., Mao, Y. X. and Yang, L.: Determination of propofol UDP-glucuronosyltransferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. J. Pharm. Biomed. Anal., 54: 236-241 (2011).